Please login to the form below

Pradaxa

This page shows the latest Pradaxa news and features for those working in and with pharma, biotech and healthcare.

Ingelheim’s thrombin inhibitor Pradaxa (dabigatran).

The business case for patient engagement

More notably, Lixiana users are far less likely to promote the drug than Xarelto or Pradaxa users, despite having a similar level of confidence in the drug as Xarelto users and ... significantly more confidence than Pradaxa users.
CHMP backs Lynparza in breast cancer, Dupixent in asthma

So far, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - is the only NOAC on the market with a reversal agent available.
Bad news for Portola as CHMP considers Factor Xa drugs

In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - remains the only new anticoagulant on the market with a reversal agent available.
Xarelto no better than aspirin in secondary stroke study

For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s
Xarelto beats aspirin for recurrent blood clots

rival NOAC Eliquis (apixaban) from Pfizer and Bristol-Myers Squibb (BMS) with 42.5%, well ahead of third place Pradaxa (dabigatran) from Boehringer Ingelheim and Daiichi Sankyo's new entrant Savaysa

More from news
Approximately 22 fully matching, plus 60 partially matching documents found.

Pharma deals during May 2014

At least the $225m will go some way towards paying for the $650m settlement of the US Pradaxa litigation Boehringer announced in May.
Interview: Allan Hillgrove, Boehringer

So far in 2013 the company has seen continued growth of its next-generation anticoagulant Pradaxa against fierce competition from rival drugs from Bristol-Myers Squibb/Pfizer and Bayer; pledged to ... American College of Cardiology (ACC) to educate
Modern anticoagulants threaten status quo

Dabigatran etexilate. Notwithstanding the initial setback for DTIs, Boehringer Ingelheim (BI) first launched its twice-daily DTI prodrug, dabigatran etexilate (Pradaxa/Pradax), in 2008.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Frontera proud finalists for the 2020 PM Awards

Meanwhile, the agency’s extensive work across multiple Boehringer Ingelheim products including Pradaxa, Spiolto and OFEV were also recognised in Film &Animation (HCPs), Mixed Media Campaign and Sales Aid categories.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Exciting Medical Writer Career Opportunity for Postdoc, Medcomms: Highly competitive salary

Add my company

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines: Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour: Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age: In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...

Email:
Password: